Revolution Medicines, Inc. (RVMDW) stock
RVMDWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMD
$9.81+0.18 (+1.82%)
Close on Oct 30, 2026Market cap $41.00BP/E –Yield –
Revolution Medicines operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Revolution Medicines's operating income for the twelve months ending Jun 30, 2026 was -$1.63B. For fiscal 2025 it was -$1.18B. The highest annual figure on record is -$40.33M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.18B | – |
| FY2024 | Dec 31, 2024 | -$689.52M | – |
| FY2023 | Dec 31, 2023 | -$487.19M | – |
| FY2022 | Dec 31, 2022 | -$258.28M | – |
| FY2021 | Dec 31, 2021 | -$188.01M | – |
| FY2020 | Dec 31, 2020 | -$110.70M | – |
| FY2019 | Dec 31, 2019 | -$54.12M | – |
| FY2018 | Dec 31, 2018 | -$40.33M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$505.13M | – |
| Q1 FY2026 | Mar 31, 2026 | -$445.22M | – |
| Q4 FY2025 | Dec 31, 2025 | -$361.63M | – |
| Q3 FY2025 | Sep 30, 2025 | -$315.27M | – |
| Q2 FY2025 | Jun 30, 2025 | -$264.71M | – |
| Q1 FY2025 | Mar 31, 2025 | -$240.76M | – |
| Q4 FY2024 | Dec 31, 2024 | -$216.31M | – |
| Q3 FY2024 | Sep 30, 2024 | -$175.71M | – |
| Q2 FY2024 | Jun 30, 2024 | -$156.64M | – |
| Q1 FY2024 | Mar 31, 2024 | -$140.86M | – |
| Q4 FY2023 | Dec 31, 2023 | -$179.98M | – |
| Q3 FY2023 | Sep 30, 2023 | -$123.25M | – |
| Q2 FY2023 | Jun 30, 2023 | -$108.80M | – |
| Q1 FY2023 | Mar 31, 2023 | -$75.16M | – |
| Q4 FY2022 | Dec 31, 2022 | -$61.71M | – |
| Q3 FY2022 | Sep 30, 2022 | -$76.53M | – |
| Q2 FY2022 | Jun 30, 2022 | -$62.09M | – |
| Q1 FY2022 | Mar 31, 2022 | -$57.95M | – |
| Q4 FY2021 | Dec 31, 2021 | -$52.91M | – |
| Q3 FY2021 | Sep 30, 2021 | -$53.16M | – |
| Q2 FY2021 | Jun 30, 2021 | -$44.54M | – |
| Q1 FY2021 | Mar 31, 2021 | -$37.40M | – |
| Q4 FY2020 | Dec 31, 2020 | -$34.08M | – |
| Q3 FY2020 | Sep 30, 2020 | -$27.55M | – |
| Q2 FY2020 | Jun 30, 2020 | -$27.98M | – |
| Q1 FY2020 | Mar 31, 2020 | -$21.08M | – |
| Q4 FY2019 | Dec 31, 2019 | -$19.56M | – |
| Q3 FY2019 | Sep 30, 2019 | -$13.56M | – |
| Q2 FY2019 | Jun 30, 2019 | -$10.56M | – |
| Q1 FY2019 | Mar 31, 2019 | -$10.44M | – |